4th Annual Chronic Kidney Disease Drug Development Summit (CKD)
Evvnt Promotion / evvnt
Archive
01.03.2022 - 03.03.2022Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 08:00 - 17:00
Conference themes As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
Professional congress organizer (PCO) Hanson Wade
Notes Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center and more.